The Phase IIb study will enroll approximately 87 participants and evaluate two therapeutic doses of psilocybin against a low-dose comparator, combined with structured psychotherapy. With multiple ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback